# Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)

> **NCT00723879** · — · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 115 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepacivirus

## Interventions

- **BIOLOGICAL:** Peginterferon alfa-2b (SCH 54031)
- **DRUG:** Ribavirin (SCH 18908)
- **BEHAVIORAL:** Patient assistance program

## Key facts

- **NCT ID:** NCT00723879
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2004-10
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** Because of slow recruitment; Despite the study was started long time ago (Oct 2004), we have not reached the projected number of patients (150 patients)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723879, "Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00723879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*